Development-stage concept: pricing, timelines and performance visuals on this page are indicative and based on PBM literature, internal modeling and prototype testing pending final product validation.
Stimulix combines a 360° helmet with tri-spectrum medical LEDs (660 / 850 / 415 nm), a gentle pulsed electromagnetic field (PEMF) module and a photo-activating serum to stimulate growth, thicken the fiber and purify the scalp — no surgery, no pain, through photobiomodulation (PBM, formerly LLLT) and low-intensity electromagnetic stimulation. The protocol is designed to reactivate follicular metabolism, improve scalp microcirculation and support a denser, healthier-looking hair cycle in short, repeatable sessions.
*Indicative results based on photobiomodulation literature and combined use of red / NIR / blue light with topical actives. To be confirmed by clinical studies.
Stimulix is a wellness and cosmetic device concept. It is not a medical treatment for alopecia, and results may vary depending on alopecia stage, age, adherence and scalp condition. Consult a dermatologist in case of pathological hair loss.
The system is based on photobiomodulation (PBM, formerly LLLT): red and near-infrared photons are absorbed by cytochrome c oxidase (complex IV of the mitochondrial respiratory chain), which releases nitric oxide (NO), increases ATP production and modulates reactive oxygen species (ROS). Result: follicles exit the telogen phase, the anagen phase is extended and the scalp microenvironment is purified. Each wavelength has a specific function.
Red light penetrates the superficial dermis (≈3–5 mm). Absorbed by cytochrome c oxidase, it dissociates inhibitory NO, restores electron transport and increases ATP synthesis. This awakens bulge stem cells (LGR5+, K15+), activates the Wnt/β-catenin pathway and extends the anagen phase.
NIR reaches the dermal papilla (≈5–10 mm) through a favorable optical tissue window. It reduces pro-inflammatory cytokines (TNF-α, IL-6), inhibits local 5-α-reductase, improves microcirculation and stimulates papillary dermal cells that produce VEGF and IGF-1.
Blue light targets endogenous porphyrins produced by Cutibacterium acnes and Malassezia spp. on the scalp. The excitation generates localized singlet oxygen that reduces bacterial load, regulates sebum secretion and limits seborrheic dermatitis and dandruff. Its contribution to visible regrowth is mainly indirect, by improving scalp health rather than directly driving follicular density.
LLLT uses coherent red light from diode lasers (typically 650 nm) to stimulate hair follicles. The laser energy is absorbed by cytochrome c oxidase, increasing ATP production and cellular activity. This panel summarizes adjacent literature; the Stimulix prototype itself uses LEDs rather than onboard laser emitters.
The efficacy of photobiomodulation follows a biphasic response (Arndt-Schulz law): too little light activates nothing, too much light inhibits. Stimulix targets the therapeutic window described in the literature.
Simplified cascade: light reaches the mitochondria through skin and scalp, releases the inhibitory NO bound to cytochrome c oxidase, restores ATP production and triggers pro-regenerative signaling toward the follicle.
Approximate penetration depth in soft tissues, per Anderson & Parrish (1981) and Avci (2014).
The light architecture of Stimulix does more than heat the dermis. It induces precise photochemical reactions at the core of dormant hair follicles (telogen phase).
By absorbing red (660 nm) and near-infrared (850 nm) photons, the CcO (complex IV of the mitochondrial chain) releases the nitric oxide (NO) that was blocking it. Oxygen can bind again, massively restarting ATP synthesis. The highly energy-demanding dermal papilla cells regain the fuel needed to produce keratin.
Photobiomodulation transiently modifies the redox signal (physiological ROS), activating proliferation of stem cells housed in the bulge. Activation of the Wnt/β-catenin pathway forces follicles to switch from their resting phase to a new hair growth phase (anagen).
Nitric oxide (NO) released by mitochondria also acts as a local vasodilator. In parallel, PBM stimulates the cellular machinery to produce VEGF growth factor, increasing micro-angiogenesis. The hair bulb is then massively supplied with organic nutrients.
Several randomized controlled trials (RCTs) have demonstrated the efficacy of PBM for androgenetic alopecia: Lanzafame et al. (Lasers Surg Med, 2013/2014), Jimenez et al. (Am J Clin Dermatol, 2014), Friedman & Schoenfeld-Tacher (2017), as well as a meta-analysis by Liu et al. (Lasers Med Sci, 2019) on ≈ 680 patients.
Over 12 to 26 weeks, the literature reports an average increase in hair density of +15 to +39 % (hairs/cm²), an increase in fiber diameter of +10 to +18 % and a reduction in hair loss measured by pull-test of 30 to 50 %.
PBM is non-ionizing, non-thermal and non-invasive. Reported adverse effects are rare and mild (transient warmth, tingling, dryness). Relative contraindications: drug-induced photosensitivity, pregnancy, active skin lesions, history of scalp carcinoma and active inflammatory scalp disorders.
Indicative data compiled over 12 weeks of protocol (3 sessions/week) according to photobiomodulation literature and internal usage data. These charts are illustrative projections based on PBM literature and internal modeling. Bars animate on hover.
Illustrative data / projections based on PBM literature, internal modeling and prototype assumptions. Source: meta-analytic LLLT review 2014–2023.
Illustrative phase distribution after 12 weeks of Stimulix protocol vs untreated scalp.
Illustrative normalized score out of 100. The Stimulix curve exceeds placebo from week 4 in this modeled projection.
| Criterion | Minoxidil 5% | Rogaine | Finasteride | PRP injection | Stimulix |
|---|---|---|---|---|---|
| Hair-loss reduction | |||||
| Visible regrowth | |||||
| Side effects | Irritation, hypertrichosis | Irritation, itching | Libido, hormonal | Pain, infection | None reported |
| Ease of use | |||||
| Estimated annual cost | ~ 270 $ | ~ 325 $ | ~ 380 $ | ~ 1950 $ | One-time purchase |
| Prescription required | No | No | Yes | Yes (doctor) | No |
Indicative comparison based on public literature. Stimulix is not a drug and remains a pre-commercial device concept.
Stimulix is more than a device. It is a complete protocol that combines a smart 360° photonic helmet with a serum specifically formulated to be activated by light.
A lightweight helmet inspired by skate helmet design (360° coverage, ABS shell + medical silicone lining), designed for regular home or professional-cabin use, with precise control of light parameters.
Designed for early-stage alopecia, seasonal hair loss, irritated scalps and helmet/PPE wearers.
Technical serum whose efficacy is amplified under red light: encapsulated actives (liposomes), photo-reactive and synergistic with the pathways activated by photobiomodulation.
Application: 3 drops on dry scalp, massage for 30 s, then immediate Stimulix Helmet 360° session (no rinse). pH 5.5 • paraben-free, silicone-free, allergen-free fragrance.
Potential synergistic effect with photobiomodulation; dedicated studies on this exact serum-light combination are in progress.
Cosmetic formula compliant with regulation (EC) No 1223/2009, declared in CPNP. Full INCI, proportions (% w/w) and functional role of each active. Packaged in a 30 mL amber airless bottle to preserve photosensitive actives.
| Ingredient (INCI) | Role | % w/w |
|---|---|---|
| Aqua | Solvent — ultrapure water | qsp 100 |
| Glycerin (veg.) | Humectant, carrier | 5.0 |
| Pentylene Glycol | Co-solvent, mild preservative | 3.0 |
| Niacinamide (B3) | Anti-inflammatory, skin barrier | 4.0 |
| Sodium Hyaluronate (50–200 kDa) | Scalp hydration | 1.0 |
| Centella Asiatica Extract | Asiaticoside, madecassoside — repair | 1.0 |
| Panax Ginseng Root Extract | Ginsenosides Rb1/Rg3 — dermal papilla | 1.0 |
| Serenoa Serrulata Extract (saw palmetto) | Partial 5-α-reductase inhibitor | 1.0 |
| Phenoxyethanol | Preservative (EU limit 1.0 %) | 0.7 |
| Caffeine | Vasodilator, follicular anti-DHT | 0.5 |
| Copper Tripeptide-1 (GHK-Cu) | Regeneration, angiogenesis | 0.5 |
| Tocopherol (vit. E) | Lipid antioxidant | 0.5 |
| Rosmarinic Acid (encapsulated) | Anti-inflammatory, antioxidant | 0.2 |
| Riboflavin (B2) | Photo-reactive chromophore — activated by blue 415 nm | 0.1 |
| Biotin (B7) | Keratinogenesis cofactor | 0.05 |
| Lecithin (encapsulation) | Liposomes — delivery vehicle | 0.5 |
Formulation: O/W emulsion with dominant aqueous phase, viscosity 1 200 mPa·s, pH 5.5, osmolarity 280 mOsm/L. Liposomal encapsulation (Ø ~150 nm) of rosmarinic acid, GHK-Cu and riboflavin to preserve their activity until irradiation.
100 % anhydrous formula (water-free) in a 100 mL amber airless bottle: no aqueous phase = no hydrolysis reaction, 18–24 month stability, preservatives reduced to a strict minimum. Triple action keratolytic + sebum-regulating + antifungal, complementary to the 415 nm photonic protocol.
| Ingredient (INCI) | Role | % w/w |
|---|---|---|
| 🧪 Oily phase — stable base (70 %) | ||
| Simmondsia Chinensis (jojoba) | Sebum regulator (liquid wax) | 40.0 |
| Squalane (olive-derived) | Penetration + oxidative stability | 20.0 |
| Caprylic/Capric Triglyceride (MCT) | Non-rancid fluidizer | 10.0 |
| 🔥 Anti-sebum active phase (29 %) | ||
| Salicylic Acid (encapsulated, lipid-soluble) | Keratolytic, dissolves intra-follicular sebum | 2.0 |
| Niacinamide (lipid-soluble) | ↓ sebaceous gland activity | 4.0 |
| Zinc PCA | Antibacterial + sebum-regulating | 3.0 |
| Bakuchiol | Natural non-irritating retinoid — ↓ sebogenesis | 2.0 |
| Melaleuca Alternifolia Oil (tea tree) | Antifungal (Malassezia spp.) | 1.0 |
| Citrus Limon Peel Oil (lemon)* | Astringent + sebum-regulating | 1.0 |
| Rosmarinus Officinalis (CO₂ extract) | Antioxidant + anti-sebum | 0.5 |
| Urtica Dioica (nettle, CO₂) | ↓ sebum secretion | 0.5 |
| Arctium Lappa (burdock, CO₂) | Anti-inflammatory + sebum-regulating | 0.5 |
| Salvia Officinalis (sage, CO₂) | Regulates sebaceous glands | 0.5 |
| 🛡️ Stabilization (1 %) | ||
| Tocopherol (vit. E) | Antioxidant — 18–24 month stability | 1.0 |
* Fresh option: replace lemon with Mentha Piperita Oil (peppermint) at 1 %. Available booster variants: liposoluble azelaic acid, encapsulated retinal, lipohydroxy acid (LHA).
Combined protocol: Sebo-Control in the evening (D1, D3, D5) → Stimulix Serum + 360° helmet in the morning. The duo cleanses the scalp (sebum, Malassezia) then stimulates regrowth.
The local action of photobiomodulation is an ideal complement to approved medical treatments (pharmacology) for androgenetic alopecia.
Action: Peripheral vasodilator, it prolongs the anagen phase (growth) and delays the telogen phase.
PBM Synergy: Red light increases micro-circulation and skin permeability, allowing better absorption of the lotion. Apply topical Minoxidil only after the helmet session, on a fully dry scalp.
⚠️ Caution — Sebo-Control + topical Minoxidil: Sebo-Control contains salicylic acid (2 %, keratolytic) and essential oils (tea tree, lemon) that transiently reduce skin barrier function. Topical Minoxidil, typically formulated with propylene glycol (already an irritant), applied on a freshly exfoliated scalp significantly raises the risk of contact dermatitis. Do not apply topical Minoxidil within 8 hours of Sebo-Control use. Use on separate days. Oral Minoxidil is not subject to this restriction. Consult your dermatologist if combining both.
Action: 5-alpha reductase inhibitors. They block the conversion of Testosterone to DHT (responsible for follicular miniaturization).
PBM Synergy: Two-level biochemical action. The drug stops the hormonal trigger (DHT) while the helmet restarts the energy machinery (ATP) to thicken the saved hair.
Action: Injection of platelet-rich plasma to stimulate stem cells, or extraction surgery (FUE/FUT).
PBM Synergy: The anti-inflammatory effect of post-operative PBM considerably accelerates tissue healing, reduces redness and boosts the survival of transplanted grafts.
Stimulix is positioned as a non-invasive hair regeneration technology, at the intersection of advanced cosmetics, medical light and connected devices.
Men 25–55 with early-stage alopecia, post-partum women, people prone to seasonal hair loss or irritated scalp, helmet and PPE wearers.
Hair clinics, dermatologists, premium salons, specialized e-commerce, serum subscription + device maintenance programs.
Stimulix Pro (720° high-density LED helmet), Stimulix Pocket (beard & temples), Stimulix Clinic (high-power version for professionals).
PBM reactivates dormant or miniaturized follicles — it cannot regenerate follicles that are fully and permanently destroyed. Early to moderate stages offer the greatest benefit potential. A dermatologist consultation is recommended to confirm staging before starting.
Stages I–IV (early to moderate recession / vertex): optimal target — follicles are miniaturized but viable. Stages V–VI: limited results expected. Stage VII (complete crown loss): not recommended — irreversible follicular destruction.
Ludwig I (mild diffuse thinning at crown) and II (moderate): primary target, best expected response. Ludwig III (severe diffuse loss, visible scalp): limited benefit. Post-partum telogen effluvium also responds well at any stage.
PBM efficacy is directly linked to residual follicle viability. The sooner treatment begins in the hair cycle decline, the greater the potential response. Hair trichoscopy is the recommended staging tool.
Increased density, reduced shedding, reactivated follicles: the benefits observed with hair photobiomodulation are quantifiable after 12 weeks of regular use (3 to 4 sessions per week).
Average increase after 12 weeks of regular use.
Significant reduction observed from the first weeks in clinical settings.
More active follicles after only 12 weeks of treatment.
Every detail has been designed to combine clinical performance, daily comfort and device elegance.
Optimized distribution for uniform and maximum scalp coverage.
AI-powered progress tracking, personalized programs and smart reminders.
Under 400 g. Optimal comfort even during extended sessions.
Temperature sensors and integrated eye protection (IEC 62471 compliant). Current status: cosmetic & wellness device — no therapeutic claims. Target Stage 2: CE Class IIa medical certification (EU MDR 2017/745) to enable direct alopecia treatment claims.
To ensure optimal clinical results and the longevity of your device, strictly follow this daily protocol and maintenance instructions.
If using Sebo-Control serum, apply it the evening before (D1, D3, D5). The next morning, on dry (or damp but towel-dried) hair, apply 2 to 3 drops of Photo-activating serum with protective actives before the photobiomodulation session.
Place the Stimulix 360° helmet on your head. Adjust the occipital dial (head circumference 52–62 cm). The medical silicone micro-studs should be in gentle contact with the scalp to effectively part the hair.
Start your program (e.g. Boost mode, 7min) via the button or the app. The 150 medical-grade LEDs deliver the calibrated dose (3–7 J/cm²). The device monitors temperature and automatically shuts off once the irradiation cycle is complete. Avoid looking directly at the LEDs.
After each use, gently wipe the front panel and studs with a slightly damp cloth (do not use chemical solvents). Charge the device once a week (battery life of 10 sessions of 7min). Store away from direct sunlight. LED array target lifetime: approximately 50,000 hours, pending final production validation.
Stimulix is the result of multidisciplinary development: medical optics, cosmetic formulation, ergonomics and embedded electronics. Each sub-system was designed, prototyped and internally tested before clinical validation.
Analysis of more than 60 publications on hair photobiomodulation (LLLT). Selection of target wavelengths (630–680 nm, 810–850 nm, 415 nm), energy densities and optimal session durations.
Selection of medical LEDs in SMD package and spectrometer characterization. Measurement of irradiance (mW/cm²) on tissue phantom to ensure consistent energy dose across the entire scalp.
5 iterations of 3D-printed shells (PA12 + ABS) with medical silicone lining, tested on a panel of 30 skull morphologies (P5–P95 ISO 7250). Optimization of weight (250 g), LED-scalp contact and perceived warmth.
Co-developed with a cosmetics laboratory: biomimetic peptides (GHK-Cu, ginseng), encapsulated rosmarinic acid, photo-reactive riboflavin. Skin penetration tests at 630 nm (red channel); riboflavin photo-reactivity validated at 415 nm (blue channel).
Custom motherboard integrating hydration, sebum, temperature sensors and accelerometer. On-board AI model to adjust the wavelength ratio in real time and guarantee thermal safety.
Pilot study in progress over 12 weeks (n=80) with hair density measured by trichoscopy. Objective:
technical file for a CE Class IIa medical device marking (EU MDR 2017/745).
CE IIa certification is required to move from Stage 1 (cosmetic wellness device, beauty claims only)
to Stage 2 (regulated medical device, alopecia treatment claims permitted).
Stimulix goes beyond simple light emission: embedded intelligence, comfort and synergy with a photo-active serum to amplify results.
Wireless 360° helmet in ABS + medical silicone, 450 g. The PEMF module uses a low-voltage pulsed-current stage to drive an external coil, generating a low-intensity time-varying magnetic field. In the device architecture, a microcontroller sends a PWM signal to a MOSFET driver, which switches the coil in controlled pulses intended to support local comfort, scalp microcirculation and repeatable contact conditions during the session.
The exclusive ginseng peptide serum is formulated to react under red light: penetration multiplied by 3 compared to standard application without photons in internal formulation testing; clinical confirmation on the final serum-device protocol is still required.
The global hair-loss treatment market was valued at ~$10.2 B in 2024 and is projected to reach $17.8 B by 2030 (CAGR ~9.6 %). Home-use photobiomodulation devices represent a fast-growing sub-segment (~$1.8 B in 2024, estimated $4.2 B by 2030).
Estimates compiled from Grand View Research 2024, MarketsandMarkets 2023, Allied Market Research 2024. Indicative only.
| iRestore Pro | Capillus 272 | HairMax Ultima | CurrentBody LED | Stimulix | |
|---|---|---|---|---|---|
| Price (USD) | ~$1,195 | ~$999 | ~$2,511 | ~$1,219 | $895 – $945 |
| Wavelengths | 650 + 670 nm | 650 nm | 655 nm | 630 + 660 nm | 660 + 850 + 415 nm |
| LEDs / coverage | 282 LEDs, partial | 272 lasers, partial | 12-comb, manual | Flexible cap | 150 LEDs, full 360° |
| Session | 25 min | 6 – 30 min | 15 min | 25 min | 7 min |
| PEMF module | ✗ | ✗ | ✗ | ✗ | ✓ |
| Photo-active serum | ✗ | ✗ | ✗ | ✗ | ✓ |
| AI / app | Basic | ✗ | Basic | ✗ | AI-personalized |
| Recurring revenue | ✗ | ✗ | ✗ | ✗ | ✓ Serum subscription |
Competitor data sourced from public retailer listings and brand websites (May 2025). Stimulix is a pre-commercial concept; final specifications subject to change.
Global hair-loss treatment market. Projected $17.8 B by 2030 (CAGR ~9.6 %).
Home-use PBM / light-therapy hair devices, EU + North America. Projected $4.2 B by 2030.
Conservative 0.5 % of serviceable market, including serum subscription ARR. Indicative.
Device sale. Estimated gross margin 55–65 %. Covers R&D amortization and brand-building. Single purchase per customer.
Photo-active serum + Sebo-Control, consumed monthly. Estimated gross margin 70–80 %. Drives predictable ARR and high retention.
Yr 1: device + 12 months serum ≈ $1,295. From yr 2: ~$350 / yr recurring subscription. LTV/3 yr ≈ $2,000 per active user.
Two indicative pre-commercial configurations: the device alone or the complete kit with photo-active serum and AI tracking.
Indicative pricing and configuration for launch planning only. Commercial availability, shipping timelines and warranty terms remain subject to final validation.
Answers to the most common questions about Stimulix.
Selection of peer-reviewed publications supporting the dosimetric, mechanistic and formulation choices of Stimulix. Non-exhaustive list — complete file available on request (NDA).
These references cover the general mechanisms and biomedical use of low-intensity pulsed electromagnetic fields; hair application remains to be validated by dedicated studies.
The cited references support the described mechanisms and the dosimetric orders of magnitude used. Stimulix is a pre-commercial cosmetic and wellness device concept; it does not replace medical advice in case of pathological hair loss (scarring alopecia, extensive alopecia areata, oncological treatments).
🔒 Secure payment